TG Therapeutics, Inc. (LON:0VGI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 5.24B +80.9% |
| Revenue (ttm) | 602.61M +76.1% |
| Net Income | 332.75M +630.2% |
| EPS | 2.09 +667.5% |
| Shares Out | n/a |
| PE Ratio | 15.75 |
| Forward PE | 25.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28 |
| Open | 56.70 |
| Previous Close | 36.65 |
| Day's Range | 56.70 - 56.70 |
| 52-Week Range | 28.07 - 56.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ... [Read more]
Financial Performance
In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.
Financial numbers in USD Financial StatementsNews
TG Therapeutics price target raised to $21 from $20 at BofA
BofA raised the firm’s price target on TG Therapeutics (TGTX) to $21 from $20 and keeps an Underperform rating on the shares. The firm adjusted targets for several companies in…
TG Therapeutics falls -10.6%
TG Therapeutics (TGTX) is down -10.6%, or -$5.51 to $46.52.
TG Therapeutics falls -10.4%
TG Therapeutics (TGTX) is down -10.4%, or -$5.40 to $46.63.
TG Therapeutics Earnings Call Transcript: Q2 2026
Q2 saw record BRIUMVI growth, with U.S. net revenue up 64% year-over-year and guidance raised to $890M-$905M. Pipeline advances included positive ENHANCE phase III data and progress on subcutaneous BRIUMVI, with expansion into new indications and strong cash reserves supporting future growth.
TG Therapeutics Earnings release: Q2 2026
TG Therapeutics released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
TG Therapeutics Quarterly report: Q2 2026
TG Therapeutics has published its Q2 2026 quarterly earnings report on August 3, 2026.
TG Therapeutics raoses FY26 revenue view to $950M from $875M-$900M
Consensus $942.51M. Raises FY26 Briumvi U.S. net product revenue view to $890M-$905M from $825M-$850M. Weiss continued, “Beyond our commercial performance, we continued to expand the long-term opportu...
TG Therapeutics reports Q2 EPS 5c, consensus 44c
Reports Q2 revenue $240.34M, consensus $229.79M. Michael S. Weiss, the company’s Chairman and Chief Executive Officer, stated, “The second quarter of 2026 was another strong quarter for TG Therapeutic...
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to ap...
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the ...
TG Therapeutics price target raised to $86 from $55 at B. Riley
B. Riley raised the firm’s price target on TG Therapeutics (TGTX) to $86 from $55 and keeps a Buy rating on the shares. The firm cites strong Briumvi demand, likely…
TG Therapeutics price target raised to $20 from $17 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on TG Therapeutics (TGTX) to $20 from $17 and keeps an Underperform rating on the shares. TG Therapeutics’ Q2 print will…
TG Therapeutics initiates Briumvi clinical trial
TG Therapeutics (TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi, in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial designed to e...
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to dise...
TG Therapeutics price target raised to $83 from $57 at Jefferies
Jefferies raised the firm’s price target on TG Therapeutics (TGTX) to $83 from $57 and keeps a Buy rating on the shares. Following Phase 1 subcutaneous Briumvi pharmacokinetic data, the…
TG Therapeutics Transcript: AGM 2026
Directors and auditors were approved, but the advisory vote on executive compensation failed. Voting results will be filed in a Form 8-K and made available online.
TG Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key priorities include commercial execution for BRIUMVI, advancing subcutaneous and MG programs, and expanding market share. Sub-Q product aims to double the addressable market with quarterly dosing, while operational leverage and capital allocation support growth and innovation.
TG Therapeutics announces Briumvi data, initiates clinical trial
TG Therapeutics (TGTX) announced topline Phase 1 data for Briumvi in patients with myasthenia gravis, or MG, and the initiation of a Phase 2 clinical trial evaluating Briumvi as a…
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)
TG Therapeutics rises 10.6%
TG Therapeutics (TGTX) is up 10.6%, or $3.89 to $40.53.
TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
BRIUMVI is achieving strong commercial momentum, with new SUB-Q data indicating high likelihood of phase III success and potential to double the addressable market. The company is positioned to offer both IV and SUB-Q options, targeting further growth through new dosing regimens and pipeline expansion.
TG Therapeutics announces results from Briumvi trial
TG Therapeutics (TGTX) announced pharmacokinetic, pharmacodynamic, safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab as compared to IV Br...
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 ...
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold...
TG Therapeutics publishes data analyses from ULTIMATE I, II studies
TG Therapeutics (TGTX) announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating Briumvi in treatment-naive adult patients with relapsing…